ADT-OH - CAS:18274-81-2

您当前的位置：

ADT-OH (Synonyms:5-(4-羟基苯基)-3H-1,2-二硫-3-硫酮;5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione; ACS 1)

目录号 : KCM12123 CAS No. : 18274-81-2 纯度 : ≥98%

Data Sheet SDS 产品使用指南

ADT-OH is a derivative of anethole dithiolethione (ADT) and synthetic hydrogen sulfide (HS) donor. It can be readily esterified with other moieties. For example, it can be coupled with therapeutics like nonsteroidal anti-inflammatory drugs, as in the generation of ATB-343 . ADT-OH has also been linked with a mitochondria-targeting motif to produce AP-39 , which selectively increases mitochondrial HS levels. ADT-OH is used both in cells and in animals for comparative studies with derived chimeras.

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock
25mg		In-stock
50mg		In-stock
10 mM * 1 mL in DMSO		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

4"-Isovalerylspiramycin I In-stock
Higenamine-d4 hydrochloride In-stock
Adebrelimab In-stock
Tigatuzumab In-stock
Cosdosiran In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases.

体外研究

ADT-OH (0-200 μM, 24-48 h) significantly inhibited the metastasis of TNBC cells (MDA-MB-231 and 4T1-Luci) without inducing proliferation inhibition.
ADT-OH (7.5-120 μM, 48 h) synergistically enhances the antitumor activity of celecoxib in human colorectal cancer cells HCT116.
ADT-OH promotes the self-renewal and anti-apoptotic capabilities of cultured NPCs.
ADT-OH exhibits anti-metastatic activity against malignant melanoma cells by inhibiting the FAK/Paxillin signaling pathway.

体内研究

ADT-OH (10-30 mg/kg, intraperitoneal injection, daily) demonstrated potent anti-metastatic activity in three distinct mouse models: the MDA-MB-231 orthotopic xenograft model, the 4T1-Luci orthotopic model, and the 4T1-Luci tail vein metastasis model.

Animal Model:	MDA-MB-231 orthotopic xenograft model, the 4T1-Luci orthotopic model and the 4T1-Luci tail vein metastasis model
Dosage:	10, 20, 30 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Had limited effect on the growth of primary tumors, but could significantly suppress the metastasis of MDA-MB-231 tumors. Had no significant effect on body weight of mice.

分子式

C₉H₆Os₃

分子量

226.35

CAS号

18274-81-2

中文名称

5-(4-羟基苯基)-3H-1,2-二硫-3-硫酮

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (552.25 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.4180 mL	22.0900 mL	44.1800 mL
5 mM	0.8836 mL	4.4180 mL	8.8360 mL
10 mM	0.4418 mL	2.2090 mL	4.4180 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂：10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 2.08 mg/mL (9.19 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (9.19 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (9.19 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (9.19 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。